Spinocerebellar ataxia type 17 (SCA17) is a type of autosomal dominant cerebellar ataxia (ADCA) characterized by variable manifestations, including cerebellar ataxia, dementia, and psychiatric symptoms. Since the identification of a CAG repeat expansion in the TATA-box binding protein (TBP) gene in a patient with ataxia in 1999 and then verification of this expansion in patients with SCA17 in 2001, several SCA17 rodent models, including both knock-in and transgenic models in mice and rats, have been established to explore the phenotypic features and pathogenesis of SCA17. These animal models revealed different pathological changes and phenotypes that are associated with the expression of mutant TBP protein and the CAG repeat lengths. It is important to understand how mutant TBP can cause differential pathological events in SCA17 animal models. In this review, we summarize and compare these animal models for the nature of transgenes and their expression as well as phenotypical features. We also discuss potential directions for future studies. V C 2016 Wiley Periodicals, Inc.
INTRODUCTION
Spinocerebellar ataxia type 17 (SCA17) is a neurodegenerative disease caused by expansion of CAA/CAG repeats that are translated to an expanded polyglutamine repeat in TATA-box binding protein (TBP). Based on Harding's classification (Whaley et al., 2011) , SCA17 belongs to type 1 ADCA (autosomal dominant cerebellar ataxia/spinocerebellar ataxia), featuring cerebellar syndrome and other neurologic symptoms such as pyramidal and extrapyramidal signs, ophthalmoplegia, and dementia. Type 1 ADCA is divided into 21 subtypes, including SCA1-SCA4, SCA8, SCA10, SCA12-SCA14, SCA15/ 16, SCA17-SCA23, SCA25, SCA27, SCA28, and dentatorubral pallidoluysian atrophy (Whaley et al., 2011) .
In 1999, an expanded CAG repeat in the TBP gene was identified in a 14-year-old Japanese female patient with progressive ataxia and intellectual deterioration (Koide et al., 1999) . In 2001, Nakamura et al. verified this abnormal CAG expansion in the TBP gene in four Japanese pedigrees with SCA17 (Nakamura et al., 2001 ). Since then, more patients with SCA17 with complex clinical features and neuropathological changes were found to have this CAG repeat expansion in the TBP gene (Fujigasaki et al., 2001; Zuhlke et al., 2001; Silveira et al., 2002; Rolfs et al., 2003; Bauer et al., 2004; Bruni et al., 2004; Lasek et al., 2006; Toyoshima et al., 2004) .
The normal repeat number in the TBP gene varies from 25 to 40, reduced-penetrance alleles range from 41 to 48, and full-penetrance alleles carry more than 48 CAG/CAA repeats that can lead to SCA17. The configuration of the repeat sequence in TBP is (CAG)3 (CAA)3 SIGNIFICANCE Spinocerebellar ataxia type 17 (SCA17) belongs to the family of neurodegenerative diseases caused by polyglutamine expansion and represents a devastating disease family without effective therapeutic treatments. Over the past two decades, remarkable efforts have been devoted to understand the mechanisms underlying SCA17 pathogenesis, with the hope of eventually finding a cure for SCA17. In particular, the generation of various rodent models provides a valuable platform for conducting such research. In the review, we summarize the current rodent models of SCA17, with the aim of facilitating future basic and preclinical studies of SCA17, which could also be informative for the study of other neurodegenerative diseases.
(CAG)x CAA CAG CAA (CAG)y CAA CAG in which X ranges from 7 to 11 and Y ranges from 9 to 21 (Fig. 1 ). This domain is divided into five segments, in which the most frequent expansion occurs in domain IV (van Roon-Mom et al., 2005) and the CAA CAG CAA interruption (domain III) works as a stabilizer for transmission between generations (Maltecca et al., 2003; Gao et al., 2008) . Therefore, depending on the absence or presence of domain III, two subtypes of TBP gene mutation were determined: type I with domain III, and type II without domain III. Type I is more prevalent than type II (Gao et al., 2008) , and type II features unstable transmission, leading to intergenerational instability in German and Italian families (Maltecca et al., 2003) . As a general transcriptional factor, TBP protein works as a critical part of the preinitiation complex with polymerase II and other molecules, which bind to the TATA box to initiate transcription (Roeder, 1991; Gostout et al., 1993) .
The clinical features of SCA17 are broad and variable. Patients with SCA17 present a variety of prominent symptoms in an age-dependent manner. Like other polyQ diseases, most SCA17 cases show late-onset and progressive symptoms. The most frequently observed clinical symptom is cerebellar ataxia, and other clinical symptoms include dementia, psychiatric symptoms, pyramidal signs, abnormal movements, parkinsonism, and epilepsy (Koide et al., 1999; Rolfs et al., 2003; Bruni et al., 2004; Stevanin and Brice, 2008) . Variable clinical features overlap with those in other neurodegenerative diseases, especially Huntington disease, leading to difficulty in clinical diagnosis of SCA17 (Stevanin and Brice, 2008) .
The neuropathological lesions are present mainly in the cerebellum and cortex, with mild alteration in the brain stem, which is consistent with the most frequently observed ataxia symptoms. Within the cerebellum, Purkinje cells show the most severe degeneration, while mild neuronal loss has been observed in the dentate nucleus and granular layers (Stevanin and Brice, 2008) . In the cerebral cortex, abnormal arborization of neuronal dendrites and spongiosis are present in the motor cortex and visual areas (Fujigasaki et al., 2001; Bruni et al., 2004; Toyoshima et al., 2004) . In the brain stem, the locus coeruleus and the substantia nigra are affected mildly (Stevanin and Brice, 2008) .
Emerging clinical reports in SCA17 pedigrees have revealed more complex symptoms in SCA17 disease. However, we still have little knowledge about the pathogenesis of SCA17, which hinders the development of effective therapy for the treatment of this disease. Animal models that express mutant TBP are highly valuable for us to understand SCA17 pathogenesis and find an appropriate treatment. Over the past 15 years, a number of different animal models of SCA17, including both knock-in and transgenic rodent models with different polyQ repeat numbers in TBP, have been generated and characterized. It would be interesting to compare these animal models to better understand how mutant TBP can elicit different neuropathology and symptoms in different animal models. In this review, we focus on the genetically modified rodent models of SCA17 and discuss their genotypic and phenotypic features, which may help in the selection of SCA17 animal models for future studies and the development of SCA17 treatment.
GENERATION OF SCA17 ANIMAL MODELS
The identification of the CAG repeat expansion in the TBP gene allows for generating SCA17 animal models via genetic modification approaches. Basically, the transgenic approach is to overexpress exogenous mutant TBP in animals to mimic SCA17 neuropathology and behavior phenotypes. Gene targeting is used to insert a large CAG repeat in the endogenous TBP gene in mice to create knock-in models that express mutant TBP at the endogenous level. Animal models created by these different approaches can recapitulate some phenotypes of SCA17 patients but also have limitations in mimicking the full range of disease features of SCA17, which will be discussed below.
Transgenic rodent models of SCA17
In 2007, Friedman et al. generated the first SCA17 mouse model that expressed human TBP (hTBP) cDNAs with 13, 71, or 105 CAG repeats under the control of the mouse prion promoter (Friedman et al., 2007) . These mouse models can recapitulate SCA17 both genotypically and phenotypically in a repeat length-dependent manner, as TBP-105Q mice show more severe genotypes than TBP-71Q mice (Table I) .
These transgenic SCA17 mice show severe neurological symptoms and early death. For example, the transgenic mouse model showed early lethality (11.5 weeks for TBP-71Q, and as early as 9 weeks for TBP-105Q). Importantly, these transgenic SCA17 mice display TBP accumulation and aggregation in the brain, an important feature of patients with SCA17. In the TBP-71Q and TBP-105Q mice, both soluble and aggregated forms of The repeat sequence of TBP is divided into five domains, including three fixed domains (I, III and V) and two variable domains (II and IV). The repeat number of CAG in domain II ranges from 7 to 11, while it ranges from 9 to 21 in domain IV. Based on the absence of domain III or not, TBP has two subtypes, subtype I with domain III and subtype II without domain III. mutant TBP can be detected in various brain regions, including the cerebellum, cerebral cortex, striatum, and brain stem, though cerebellum has the highest expression level (Table I ). The severe phenotypes of these SCA17 mice are likely due to the overexpression of transgenic mutant TBP driven by the prion promoter.
After the generation of the first SCA17 mouse model, Chang et al. generated another SCA17 (L7-hTBP) transgenic mouse model. They used a construct carrying the cDNA encoding hTBP with a polyQ (109Q) repeat under the control of the Purkinje-specific protein (Pcp2/L7) gene promoter (Chang et al., 2011) , which can drive transgene expression mainly in the Purkinje cells (Walton et al., 2012) . As a result, the expression of mutant TBP occurred mainly in the cerebellum and brain stem in L7-hTBP transgenic mice.
In 2013, Kelp et al. generated the TBP-64Q transgenic rat model, in which a construct carrying full-length hTBP with 64 CAG repeats driven by the murine prion promoter was used. The expression of mutant TBP was mainly found in the cerebellum, with moderate expression in the cortex and olfactory bulb, while very low levels of mutant TBP were found in the hypothalamus, brain stem, and striatum. As opposed to the transgenic mouse models, the transgenic rat model showed that mutant TBP was mainly present in the granular and molecular layers, with a low level in the Purkinje layer (Kelp et al., 2013) . The expression of transgenic mutant TBP in the above rodent models depends on the copy number and chromosomal location of transgenes under different promoters. Also, the repeat numbers in these transgenic mutant TBP models are not the same. Thus, we compare the phenotypes and neuropathology of these transgenic SCA17 rodent models (TBP-71Q, TBP-105Q, L7-hTBP, TBP-64Q rat) in Table I . In TBP-71Q and TBP-105Q mice, mutant TBP formed aggregates in an age-dependent manner, with the decreased expression of soluble mutant TBP (Friedman et al., 2007) . Both TBP-71Q and TBP-105Q mice displayed decreased life span and body weight loss, while TBP-105Q mice showed such phenotypes earlier than TBP-71Q mice. Both TBP-71Q and TBP-105Q mice were found to have spontaneous seizures and tremor phenotypes. In the L7-hTBP mice, the phenotypes are less severe, and the hunchback phenotype was not described. For the motor deficits, all the mouse models showed poor performance in a rotarod test. They also displayed typical clasping phenotypes, and gait disturbance abnormalities were found in the L7-hTBP mice by footprinting assay. Similar to the transgenic mouse models, the transgenic rat model also displayed severe phenotypes including kyphosis, decreased life span, and body weight loss, though the rat model carries a smaller CAG repeat. A wide array of behavior tests have been performed to elucidate both motor and nonmotor defects in the SCA17 rat model. For example, the transgenic rat model was evaluated with a modified ataxia score test and elevated plus maze (EPM) test, and their ataxia phenotype was quantitatively analyzed.
For the neuropathological characterization, no differences in the gross brain morphology were reported in all transgenic rodent models compared with their wildtype littermates. As SCA17 mainly affects the cerebellum, studies of all these models focused on the neuropathy in the cerebellum. Gliosis and cerebellar degeneration were detected using different methods, including fluorescent staining or electron microscopy (Chang et al., 2011; Friedman et al., 2007) . In the TBP-71Q and TBP-105Q mice, degenerated Purkinje cells and axons were observed, while degenerated neurons with nuclear inclusions were observed only in the cerebellar granular layer in TBP-105Q mice. Moreover, the TBP-105Q protein formed prominent nuclear inclusions, whereas the TBP-71Q protein remained largely diffuse in the neuronal nuclei. Because of the larger brain size in rats, positron emission tomography (PET) and diffusion tensor imaging (DTI) data were collected from TBP-64Q transgenic rat models. The highlight of this rat model is that PET and DTI analysis was conducted, confirming the possibility of using DTI results as a potential biomarker for SCA17, which is also an obvious advantage of using the rat model of SCA17.
One significant concern about using transgenic mouse models to study SCA17 pathogenesis is the overexpression of mutant TBP controlled by exogenous promoters, as in the research field of neurodegenerative proteinopathies, it is becoming increasingly recognized that the overexpression of mutant proteins could lead to artificial phenotypes. This concern is even more justified based on studies showing that overexpression of wildtype polyQ proteins caused disease-like phenotypes in animal models as well (Fernandez-Funez et al., 2000; Monks et al., 2007; Nedelsky et al., 2010) . Therefore, knock-in models that express mutant TBP driven by its endogenous promoter are more likely to recapitulate toxicity under physiological conditions, and are preferable in terms of studying SCA17 pathological mechanisms. Nonetheless, the relatively low cost and short turnaround time make it possible to generate transgenic models using different model organisms, which is ideal for studying different aspects of SCA17 pathology. Moreover, the rapidly progressive phenotypes commonly found in such models make them good a fit for the initial screening of potential therapeutic targets for SCA17 treatment.
SCA17 knock-in mouse model
In 2011, a knock-in mouse model of SCA17 was generated and expected to most closely recapitulate SCA17 genetically (Huang et al., 2011) . This knock-in SCA17 mouse model uses the Cre-loxP technique, which allows for tissue-and time-specific expression of mutant TBP (Yang et al., 2014; Huang et al., 2015) . In the knock-in mouse model, the mouse TBP exon 2 was replaced with human TBP exon 2 carrying 105 CAGs (Huang et al., 2011) . Three stop codons that are flanked by two loxP sites were placed in the front of the translation initiation site. The heterozygous floxed (TBP-105Q 1/loxp ) mice were crossed with transgenic mice expressing Cre under the control of the neuronal nesting promoter. Thus, expression of Cre can remove the stop codons flanked by loxP sites and activate the expression of mutant TBP in neuronal cells in SCA17 knock-in mice (Huang et al., 2011) .
Compared with transgenic SCA17 mouse models in which mutant TBP was overexpressed, mutant TBP in the knock-in mice is expressed at the endogenous level. There is diffuse staining of mutant TBP in the nuclei of the cortex, striatum, brain stem, and cerebellum, with only small nuclear aggregates found in Purkinje cells (Huang et al., 2011) . This knock-in mouse model had similar but later-onset phenotypes compared with transgenic mouse models (Table II) . Compared with the transgenic models, this knock-in mouse model displayed milder neurological symptoms and neurodegeneration, perhaps because mutant TBP expression is at the endogenous level and is also restricted to neuronal cells.
In 2014, Yang et al. generated an inducible TBP knock-in mouse model by crossing the floxed TBP mice with Cre-ER transgenic mice that express tamoxifeninducible Cre throughout the body so that mutant TBP expression can be turned on at different ages by intraperitoneal injection of tamoxifen (Yang et al., 2014 ). This mouse model was used for research on the age-related effects of mutant TBP. The authors found that the neurological phenotypes as well as cerebellar neuronal degeneration were all age-related processes. The older the mice were, the faster the mutant TBP accumulated in the neuronal cells. In other words, the aged mice showed more severe neurological phenotypes in a shorter period of time after tamoxifen injection compared with young knock-in mice.
In 2015, Huang et al. reported the generation of germline TBP knock-in mice by crossing the floxed TBP mice with transgenic mice expressing Cre under the control of the EIIa promoter, which drives the expression of Cre in early embryonic cells. Therefore, mutant TBP can be expressed ubiquitously at the endogenous level in the crossed mice (Huang et al., 2015) . In this mouse model, the presence of mutant TBP reduced the level of wild-type TBP in mouse brains, which was also reported previously in the transgenic mice, indicating that TBP is an important transcriptional regulator and that its protein level is tightly controlled in the body. Moreover, in the germline TBP knock-in mice, mutant TBP was found to preferentially accumulate in the nuclei of neuronal and muscle cells and exerted polyQ length-dependent toxic effects in the brain and muscle tissues (Huang et al., 2015) .
All TBP knock-in mice showed SCA17-related phenotypes, including hunchback or kyphosis, body weight loss, deceased life span, and motor deficits. However, the germline knock-in mice displayed more severe and earlier-onset phenotypes than neuron-specific knock-in mice, suggesting an important role of peripheral mutant TBP in the pathogenesis of SCA17. Indeed, the skeletal muscle degeneration appears to be a more significant symptom that can cause early death of SCA17 knock-in mice. Since muscle atrophy could also be due to the degeneration of motor neurons that can result in denervation of the muscle, Huang et al. explored whether the muscle degeneration is the primary effect of mutant TBP or secondary to the motor neuron degeneration. They crossed the floxed TBP mice with muscle-specific Cre transgenic mice and found that the muscle-specific expression of mutant TBP produced the same muscle atrophy phenotype. Also, electron microscopic study and immunohistochemical staining did not uncover any abnormal structures in the neuromuscular junction (Huang et al., 2015) .
The significant muscle degeneration in SCA17 knock-in mice could be polyQ repeat length dependent. In support of this idea, direct expression of mutant TBP with 44Q in muscle cells via viral infection did not elicit obvious muscle phenotypes. Also, juvenile SCA17 patients with > 63Q showed symptoms such as muscle weakness and seizure (Koide et al., 1999; Maltecca et al., 2003) , supporting the idea that the peripheral or muscle phenotypes of SCA17 patients are polyQ length dependent and explaining why most SCA17 patients carrying 43 to 48 CAGs do not show an obvious muscle atrophy phenotype. These findings provide strong evidence that mutant TBP protein with a large polyQ repeat could directly affect peripheral tissues and produce more complex phenotypes.
As evidenced by the above studies, knock-in models enable us to understand the molecular mechanisms that are closely relevant to SCA17 pathogenesis, which brings valuable insights into the development of potential The age of mice when a specific phenotype was first observed is indicated in the table. NS: The age was not mentioned in the original publication.
therapeutic strategies for SCA17 treatment. Nonetheless, generating knock-in models is time-and moneyconsuming. Also, because of the endogenous expression of mutant TBP, the toxicity develops slowly, and the symptoms normally appear at a much later stage. It is also possible that the rodent brain is less vulnerable than the human brain to polyQ disease proteins. Thus, to ensure that the disease phenotypes could occur within the life span of the mice, an extremely extended CAG repeat (105 repeats) was used, which may not fully recapitulate the conditions of most SCA17 patients with moderate repeat numbers.
CONCLUSION AND FUTURE PERSPECTIVES
Genetically modified rodent models of SCA17 provide us with valuable tools to further investigate SCA17 pathogenesis and to develop the treatment of SCA17 (Fig. 2) . Because SCA17 represents a family of polyQ diseases and the function of TBP has been well characterized, investigation of SCA17 will also provide broad insight into other polyQ diseases. Using these SCA17 rodent models, we can address an important issue regarding how a ubiquitously expressed polyQ protein can cause selective pathology in an age-dependent manner. The current genetic animal models of SCA17 clearly indicate that the phenotypes are dependent on the expression levels of mutant TBP and the length of CAG/glutamine repeat. It should also be pointed out that phenotype assays are important to reveal the effects of mutant TBP. As motor deficit is the most prominent symptom in patients with SCA17, several assays can be used for evaluating motor coordination deficits, including the rotarod test, balance beam, and footprinting assay. The rotarod test is the commonly used method to test motor coordination in mouse models, which can be divided into nonaccelerating and accelerating versions (Brooks and Dunnett, 2009 ). The original version for the rotarod test is the nonaccelerating test with a set speed, which is not suitable for poor coordination animals, as the animals can fall off at the beginning of the test. Thus, the nonaccelerating test makes the result a representation of endurance rather than coordination. To overcome this problem, an accelerating version has been designed, which can better Fig. 2 . A brief summary of our current understanding of SCA17 molecular pathogenesis and potential therapeutic options by studying SCA17 mouse models. (a) In TBP-71Q and TBP-105Q TG mice model, there was enhanced interaction of mutant TBP with TFIIB, a transcriptional factor. Also, there was decreased level of Hsp27(HSPB1), which is essential for axonal and neurotic integrity, leading to shorter neurites. When they overexpressed HSBP1, the shortened neurites were prominently rescued. (b) In L7-hTBP TG mice, granulocyte-colony stimulating factor(G-CSF) treatment was shown to improve the neurological behavior of SCA17 mice, which has been identified to be beneficial in many animal models of neurodegenerative diseases. Meanwhile, there was an increased level of p-ERK in the cerebella of transgenic mice after G-SCF treatment.
(c) In germline TBP KI mice, mutant TBP abnormally interacted with MyoD and reduced its level. When MyoD was overexpressed, the muscle degeneration in SCA17 KI mice was alleviated. (d) In nestin TBP KI mice, they found that mutant TBP bound more tightly to nuclear factor-YA(NF-YA), a subunit of the transcription factor NF-Y. Also, mutant TBP inhibited NF-YA transcriptional activity, leading to the reduced chaperone protein levels (Hsp70, HspA5) whose expression were regulated by NF-Y. (e) In inducible TBP KI mice, expanded polyQ disrupted the association between TBP and XBP1s, impaired the transcription of MANF and decreased chaperone activity (Hsp70 and Hsp90). When Manf expression was restored, mutant TBP toxicity was ameliorated in vitro and in vivo. evaluate motor coordination (Shiotsuki et al., 2010) . In addition to motor deficits, psychiatric symptoms are also present in patients with SCA17. In recently established rodent models, especially in the rat model of SCA17, several tests, such as the EPM test and PhenoMaster system, have been performed to measure nonmotor symptoms.
Characterization of pathological changes is also important to reveal the in vivo toxicity of mutant TBP. Identification and quantification of soluble and aggregated forms of mutant TBP in different tissues would help us to understand how mutant TBP mediates tissue-or celltype-specific pathology. Such a study relies on the use of antibodies to different forms of mutant TBP. Four antibodies were reported for TBP detection, including N-12, 1C2, 1TBP18, and EM192 (Friedman et al., 2008) . All three antibodies (N12, 1C2, and 1TBP18) can be used to detect both soluble and aggregated forms of TBP in Western blotting and immunostaining (Table III) . The N-12 antibody was used for the detection of the Nterminus of TBP of human origin. The 1C2 antibody was generated against the polyQ region and, therefore, can also be used for detecting other polyglutamine disease proteins. The epitope of 1TBP18 is located in amino acid residues 1 to 20 of human, mouse, and rat TBP. EM192 was developed in the Li Lab at Emory University and had been used for detecting the C-terminal fragment of TBP (Friedman et al., 2008) .
The genetically modified SCA17 rodent models will allow us to investigate how tissue-specific expression of mutant TBP contributes to SCA17 symptoms and phenotypes (Yang et al., 2016) . The relatively milder phenotypes of SCA17 mice that express mutant TBP primarily in neuronal cells compared those in SCA17 mice that express mutant TBP ubiquitously indicate that the peripheral effects of mutant TBP critically contribute to the progression and severity of SCA17. Although these SCA17 mouse models have revealed the toxic effects of mutant TBP in skeletal muscle, it remains to be investigated whether mutant TBP also affects other types of cells. Understanding this issue would be important to test the idea that polyQ proteins may preferentially affect postmitotic cells, such as neurons and muscle cells. Since SCA17 knock-in mice show much more severe muscle atrophy than other polyQ diseases, such as in the Huntington disease mouse model, it is clear that protein context also defines the specific pathology in each polyQ disease. One possibility for this peripheral phenotype is that a large polyQ repeat can confer additional or unique toxicity or phenotypes that are different from those mediated by intermediate-length polyQ repeats. This possibility should be rigorously tested by generating additional knock-in mouse models that express mutant TBP with different lengths of polyQ tracts. Also, there may be cell-type or tissue-specific proteins whose function is differentially affected by TBP with different lengths of polyQ tracts. The current and future SCA17 mouse models that express mutant TBP selectively in different types of cells or tissues should provide us with tools to address this important issue. Finally, since TBP is a well-studied transcription factor, studying SCA17 animal models has the potential to provide mechanistic insights into other polyQ diseases that share a number of common phenotypic and pathological aspects. 1 Indicates the antibody works for that particular application; 2 indicates the antibody does not work for that particular application.
